DOI: 10.1002/art.41158 [Google Scholar] Farah H, Wijesinghe SN, Nicholson T, Alnajjar F, Certo M, Alghamdi A, et al
A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus
That can stress an already weak heart
A typical strategy is a short trial, evaluate response, then repeat cycles as clinically indicated while addressing lifestyle and underlying drivers
For instance, in a clinical randomized trial of 52 patients with T2D, 16S rRNA profiling showed that 6 weeks of liraglutide (or colesevelam) did not produce discernible changes in gut microbiota composition, even though patients experienced altered bile acid profiles ( However, another study in diabetic patients showed functional genetic predictions indicating that liraglutide might increase microbial genes associated with improved carbohydrate and lipid metabolism, suggesting a shift toward a healthier functional capacity of the gut microbiota ( Other human studies have reported microbiota changes concordant with those seen in animal models
Tesamorelin is an FDA-approved synthetic growth hormonereleasing hormone analogue that stimulates IGF-1 production to reduce visceral abdominal fat in HIV-associated lipodystrophy, though its use outside this population remains unproven